Peripheral Expression of CXCL10 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, and Ribavirin

被引:5
|
作者
Afzal, Maira [1 ]
Ali, Amjad [2 ]
Sheikh, Nadeem [3 ]
Rafique, Shazia [4 ]
Idrees, Muhammad [4 ]
机构
[1] Univ Punjab, Ctr Appl Mol Biol CAMB, Mol Virol Lab, Lahore, Pakistan
[2] Hazara Univ Mansehra, Dept Genet, Khyber Pakhtunkhwa 21310, Pakistan
[3] Univ Punjab, Dept Zool, Lahore, Pakistan
[4] Univ Punjab, Ctr Excellence Mol Biol CEMB, Div Mol Virol, Lahore, Pakistan
来源
关键词
CXCL10; expression; HCV; DAAs; patients; HEPATOCELLULAR-CARCINOMA; ANTIVIRAL THERAPY; VIRUS-INFECTION; PEGINTERFERON ALPHA-2A; PEGYLATED INTERFERON; TREATMENT-NAIVE; PLUS RIBAVIRIN; VIRAL RESPONSE; IP-10; CXCL10; GENOTYPE;
D O I
10.1089/jir.2019.0185
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatitis C virus (HCV) causes persistent infection and invades host's innate and adaptive immune systems. During the eradication of this pathogen, the components of immune system may cause bystander damage to host, which might be even worse than the viral pathogenesis. Thus, the therapy should not only eliminate primary virus infection but also improve the inflammatory immune responses. The breakthrough of interferon free direct acting antiviral (DAA) drugs has provided the opportunity to unravel the association of HCV with immune response. This study aimed to examine the expression level of C-X-C motif chemokine ligand 10 (CXCL10) in the Peripheral blood mononuclear cells (PBMCs) of HCV infected patients treated with DAAs + Ribavirin. In this study we analyzed the expression levels ofCXCL10mRNA in the 90 chronic HCV patients using quantitative PCR (qPCR) prior, after, and during therapy with sofosbuvir/ribavirin (SOF+RBV) and sofosbuvir/daclatasvir/ribavirin (SOF+DCV+RBV), and further, the results were analyzed relative to treatment response. Significantly elevatedCXCL10mRNA was seen in naive patients having higher viral load (P = 0.005) and those suffering from hepatocellular carcinoma (P = 0.006). HCV patients had remarkable decline inCXCL10level after 4, 12, and 24 weeks of therapy with DAAs. An approximate one-fold decrease was observed in patients who attained sustained virological response compared to untreated patients (P< 0.0001). Comparing the 2 regimens, the reduction in peripheralCXCL10expression was more pronounced in patients undergoing SOF+DCV+RBV therapy. The current study implicitly shows the role ofCXCL10as an indicator of disruption of host-virus equilibrium and consequent pathogenesis of HCV during successful antiviral therapy. Furthermore, the drop inCXCL10level after HCV viral clearance might reflect the DAA-induced alleviation in the extrahepatic manifestation of this infection.
引用
收藏
页码:301 / 309
页数:9
相关论文
共 50 条
  • [1] Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin
    Zeremski, Marija
    Dimova, Rositsa B.
    Benjamin, Samantha
    Penney, Marina S.
    Botfield, Martyn C.
    Talal, Andrew H.
    JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (11): : 1795 - 1799
  • [2] Transcriptional Analysis of TP53 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, Pegylated Interferon, and Ribavirin
    Chudhary, Hafiza Rida Farooq
    Ali, Amjad
    Bibi, Sadia
    Waqas, Muhammad
    Rafique, Shazia
    Idrees, Muhammad
    Halim, Sobia Ahsan
    Abdellattif, Magda H.
    Khan, Ajmal
    Al-Harrasi, Ahmed
    ACS OMEGA, 2023, 8 (16): : 14784 - 14791
  • [3] Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin
    Parisi, Saverio G.
    Loregian, Arianna
    Andreis, Samantha
    Nannetti, Giulio
    Cavinato, Silvia
    Basso, Monica
    Scaggiante, Renzo
    Dal Bello, Federico
    Messa, Lorenzo
    Cattelan, Anna Maria
    Palu, Giorgio
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 49 : 151 - 153
  • [4] Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C
    Quddus, Muhammad Abdul
    Zaib, Jahangir
    Munawar, Rukhsana
    Siddiq, Shazia
    Tahir, Rabia
    Kiani, Rizwan Saeed
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (09): : 2823 - 2825
  • [5] Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?
    Ferrari, Silvia Martina
    Fallahi, Poupak
    Ruffilli, Ilaria
    Elia, Giusy
    Ragusa, Francesca
    Paparo, Sabrina Rosaria
    Patrizio, Armando
    Mazzi, Valeria
    Colaci, Michele
    Giuggioli, Dilia
    Ferri, Clodoveo
    Antonelli, Alessandro
    JOURNAL OF IMMUNOLOGY RESEARCH, 2019, 2019
  • [6] Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection
    Elbaz, Tamer
    Abdo, Mahmoud
    Omar, Heba
    Hassan, Essam A.
    Zaghloul, Amr M.
    Abdel-Samiee, Mohamed
    Moustafa, Ahmed
    Qawzae, Abdallah
    Gamil, Mostafa
    Esmat, Gamal
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (02) : 272 - 277
  • [7] Real-world efficacy of sofosbuvir and daclatasvir, with and without ribavirin for patients with chronic hepatitis C in Asia
    Chirapongsathorn, Sakkarin
    Wongpaitoon, Virasak
    Phanubol, Patamaporn
    Techapaitoon, Satien
    Sukhabote, Rujapong
    Osangthamnont, Charkaphan
    Anuras, Sinn
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 163 - 163
  • [8] Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C
    Rivero-Juarez, Antonio
    Brieva, Teresa
    Frias, Mario
    Rivero, Antonio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (09) : 901 - 910
  • [9] Safety and Efficacy of Sofosbuvir Plus Ribavirin and Sofosbuvir Plus Daclatasvir With or Without Ribavirin Combinations in Children and Adolescents With Chronic Hepatitis C
    Hassan, Adil
    Bughio, Ubedullah
    Bhatti, Rehmatullah
    Ali, Mashooque
    Jamali, Laraib
    Sadik, Muhammad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S592 - S592
  • [10] Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison
    Swallow, Elyse
    Song, Jinlin
    Yuan, Yong
    Kalsekar, Anupama
    Kelley, Caroline
    Peeples, Miranda
    Mu, Fan
    Ackerman, Peter
    Signorovitch, James
    CLINICAL THERAPEUTICS, 2016, 38 (02) : 404 - 412